

<b>National Imaging Associates, Inc.*</b>	
<b>Clinical guidelines</b> <b>HEAD AND NECK CANCER</b>	<b>Original Date: June 2013</b>
<b>Radiation Oncology</b>	<b>Last Revised Date: January 2022</b>
<b>Guideline Number: NIA_CG_131</b>	<b>Implementation Date: January 2023</b>

## INDICATIONS FOR RADIATION THERAPY

2D, 3D, IMRT and Brachytherapy techniques may be used as appropriate, depending on the tumor location and stage of disease.<sup>1</sup> Brachytherapy, where appropriate, may be utilized as a boost for 2D, 3D or IMRT courses of radiation therapy.

- Pre-operative radiation therapy
  - 2D/3D/IMRT – up to 35 fractions
- Definitive radiation therapy with or without concurrent chemotherapy
  - 2D/3D/IMRT – up to 42 fractions
    - Hyperfractionation - 81.6Gy, 1.2Gy per fraction BID (up to 68 fractions)
- Post-operative radiation therapy (up to 40 fractions)
  - Presence of adverse factors
    - pT3 or pT4 primary tumors
    - N2-3
    - Perineural invasion
    - Vascular tumor embolism
    - Extracapsular spread
    - Positive surgical margin
- Palliative radiation therapy if symptomatic up to 20 fractions

## TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW

### Stereotactic Body Radiation Therapy (SBRT)

Stereotactic Body Radiation Therapy is not a standard treatment option for the treatment of head and neck cancer. SBRT may be indicated for reirradiation.<sup>1</sup>

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

## Proton Beam Radiation Therapy<sup>2</sup>

Proton beam is not a standard treatment option for head and neck cancer and should not be used routinely. A physician review is required to determine medical necessity.

- Re-irradiation up to 34 fractions may be indicated if no metastatic disease present
- Advanced (e.g., T4) and/or unresectable head and neck cancers<sup>3-14</sup>
- Cancers of the paranasal sinuses and other accessory sinuses

---

## BACKGROUND

According to the American Society of Clinical Oncology, about 4% of all cancers in the United States occur in the head and neck. The majority of these tumors are squamous cell carcinoma, with human papilloma virus infection, tobacco and alcohol use regarded as risk factors.<sup>15</sup> Due to the complexity of tumors arising from the head and neck region, it is not unusual for management to include an initial evaluation and development of a plan by a multidisciplinary team, including surgery, radiotherapy, medical oncology, and dental. Although single modality treatment with either surgery or radiotherapy is not uncommon with patients with early stage disease, combined modality therapy is appropriate for the majority of patients with locally or regionally advanced stage of disease.<sup>1</sup> The primary sites for head and neck tumors include paranasal sinuses, the lip, oral cavity, salivary glands, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, nasopharynx, and occult head and neck primary sites.

This guideline outlines several methods suitable for delivering radiation therapy to the head and neck area. Various radiotherapy techniques may be used as appropriate, depending on the stage, location, and expertise of the radiation oncologist.<sup>1</sup> Multidisciplinary management is recommended to best achieve tumor control while reducing toxicity.<sup>15</sup> These are generally accepted practice guidelines, however, and cannot incorporate all possible clinical variations. Thus, they are not intended to replace good clinical judgment or individualization of treatments.

IMRT, 3D, 2D, and brachytherapy techniques may be used as appropriate, depending on the tumor location, stage of disease, and experience/availability of dosimetry/medical physics support.<sup>1</sup> Intensity modulated radiation therapy (IMRT) has been shown to be useful in reducing long-term side effects in oropharyngeal, paranasal sinus, and nasopharyngeal cancers by reducing dose to normal surrounding tissue, including the salivary gland and brain (including temporal lobes, auditory apparatus, and optic structures). The application of IMRT to other sites of the head and neck is evolving with the recommendation to use at the discretion of the treating physicians. IMRT can be delivered with various dose fractionation schemes, including simultaneous integrated boost, sequential boost, and concomitant accelerated boost. IMRT has been shown to be beneficial in treating certain head and neck cancers by reducing dose to the salivary glands, brain, auditory apparatus, and optic structures. Low dose or high dose brachytherapy may be appropriate in certain cases.

## POLICY HISTORY

Date	Summary
January 2022	Add the following under Proton Beam Radiation Therapy: <ul style="list-style-type: none"><li>• Re-irradiation up to 34 fractions may be indicated if no metastatic disease present</li><li>• Cancers of the paranasal sinuses and other accessory sinuses</li></ul>
February 2021	No Changes
February 2020	<ul style="list-style-type: none"><li>• Proton Beam Added: Proton beam is not a standard treatment option for head and neck cancer and should not be used routinely. Proton Beam may be considered for advanced (e.g. T4) and/ or unresectable head and neck cancers.</li><li>• Added and updated references</li></ul>
February 2019	<ul style="list-style-type: none"><li>• Added and updated references</li></ul>

## REFERENCES

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers Version 1.2022. National Comprehensive Cancer Network (NCCN). Updated December 8, 2021. Accessed December 10, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf)
2. American Society for Radiation Oncology. Model Policies: Proton Beam Therapy. Updated June 2017. Accessed December 8, 2021. [https://www.astro.org/uploadedFiles/MAIN\\_SITE/Daily\\_Practice/Reimbursement/Model\\_Policies/Content\\_Pieces/ASTROPBTModelPolicy.pdf](https://www.astro.org/uploadedFiles/MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/ASTROPBTModelPolicy.pdf)
3. Holliday EB, Garden AS, Rosenthal DI, et al. Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of intensity-modulated proton therapy and intensity-modulated photon therapy. *International journal of particle therapy*. 2015;2(1):19-28.
4. Russo AL, Adams JA, Weyman EA, et al. Long-Term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma. *Int J Radiat Oncol Biol Phys*. May 1 2016;95(1):368-376. doi:10.1016/j.ijrobp.2016.02.042
5. McDonald MW, Liu Y, Moore MG, Johnstone PA. Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy. *Radiat Oncol*. Feb 27 2016;11:32. doi:10.1186/s13014-016-0600-3
6. Holliday EB, Frank SJ. Proton therapy for nasopharyngeal carcinoma. *Chin Clin Oncol*. Apr 2016;5(2):25. doi:10.21037/cco.2016.03.05
7. Dagan R, Bryant C, Li Z, et al. Outcomes of Sinonasal Cancer Treated With Proton Therapy. *Int J Radiat Oncol Biol Phys*. May 1 2016;95(1):377-385. doi:10.1016/j.ijrobp.2016.02.019
8. Simone CB, 2nd, Ly D, Dan TD, et al. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. *Radiother Oncol*. Dec 2011;101(3):376-82. doi:10.1016/j.radonc.2011.05.028
9. van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. *Oncologist*. 2011;16(3):366-77. doi:10.1634/theoncologist.2010-0171
10. van der Laan HP, van de Water TA, van Herpt HE, et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study. *Acta Oncol*. Apr 2013;52(3):561-9. doi:10.3109/0284186x.2012.692885
11. Widesott L, Pierelli A, Fiorino C, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. *Int J Radiat Oncol Biol Phys*. Oct 1 2008;72(2):589-96. doi:10.1016/j.ijrobp.2008.05.065
12. Kandula S, Zhu X, Garden AS, et al. Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: a treatment planning comparison. *Med Dosim*. Winter 2013;38(4):390-4. doi:10.1016/j.meddos.2013.05.001
13. Jakobi A, Stützer K, Bandurska-Luque A, et al. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. *Acta Oncol*. 2015;54(9):1658-64. doi:10.3109/0284186x.2015.1071920

14. van de Water TA, Lomax AJ, Bijl HP, et al. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. *Int J Radiat Oncol Biol Phys*. Mar 15 2011;79(4):1216-24. doi:10.1016/j.ijrobp.2010.05.012
15. American Society of Clinical Oncology. Head and Neck Cancer: Statistics. American Society of Clinical Oncology (ASCO). Updated February 2021. Accessed December 14, 2021. <https://www.cancer.net/cancer-types/head-and-neck-cancer/statistics>

## ADDITIONAL RESOURCES

1. Salama JK, Saba N, Quon H, et al. ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. *Oral Oncol*. Jul 2011;47(7):554-9. doi:10.1016/j.oraloncology.2011.05.002
2. American College of Radiology. ACR Appropriateness Criteria: Aggressive nonmelanomatous skin cancer of the head and neck. Updated 2014. Accessed November 9, 2021. <https://acsearch.acr.org/docs/3091669/Narrative>
3. Yeung AR, Garg MK, Lawson J, et al. ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. *Head Neck*. May 2012;34(5):613-6. doi:10.1002/hed.21993
4. American College of Radiology. ACR Appropriateness Criteria®: Local-regional therapy for resectable oropharyngeal squamous cell carcinomas. Updated 2015. Accessed December 14, 2021. <https://acsearch.acr.org/docs/69505/Narrative/>
5. American College of Radiology. ACR Appropriateness Criteria®: Retreatment of recurrent head and neck cancer after prior definitive radiation. Updated 2014. Accessed December 14, 2021. <https://acsearch.acr.org/docs/69506/Narrative/>
6. American College of Radiology. ACR Appropriateness Criteria®: Thyroid carcinoma. Updated 2013. Accessed December 14, 2021. <https://acsearch.acr.org/docs/3082874/Narrative/>
7. Ridge JA, Lawson J, Yom SS, et al. American College of Radiology Appropriateness Criteria(®) treatment of stage I T1 glottic cancer. *Head Neck*. Jan 2014;36(1):3-8. doi:10.1002/hed.23381
8. Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. *Journal of Clinical Oncology*. 2010/05/20 2010;28(15\_suppl):5507-5507. doi:10.1200/jco.2010.28.15\_suppl.5507
9. Buiet G, Combe C, Favrel V, et al. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys*. Jun 1 2010;77(2):430-7. doi:10.1016/j.ijrobp.2009.04.066
10. Gomez DR, Zhung JE, Gomez J, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. *Int J Radiat Oncol Biol Phys*. Mar 15 2009;73(4):1096-103. doi:10.1016/j.ijrobp.2008.05.024
11. Hartford AC, Palisca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). *Int J Radiat Oncol Biol Phys*. Jan 1 2009;73(1):9-14. doi:10.1016/j.ijrobp.2008.04.049

12. Hitt R, Grau JJ, Lopez-Pousa A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). *Journal of Clinical Oncology*. 2009/05/20 2009;27(15\_suppl):6009-6009. doi:10.1200/jco.2009.27.15\_suppl.6009
13. Holmes T, Das R, Low D, et al. American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments. *Int J Radiat Oncol Biol Phys*. Aug 1 2009;74(5):1311-8. doi:10.1016/j.ijrobp.2009.04.037
14. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin*. Jan-Feb 2012;62(1):10-29. doi:10.3322/caac.20138
15. Lefebvre J, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. *Journal of Clinical Oncology*. 2009/05/20 2009;27(15\_suppl):6010-6010. doi:10.1200/jco.2009.27.15\_suppl.6010
16. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. *J Natl Cancer Inst*. Feb 4 2009;101(3):142-52. doi:10.1093/jnci/djn460
17. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. *Int J Radiat Oncol Biol Phys*. Feb 1 2009;73(2):424-32. doi:10.1016/j.ijrobp.2008.04.037
18. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. *Lancet Oncol*. Feb 2011;12(2):127-36. doi:10.1016/s1470-2045(10)70290-4
19. Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. *Ann Oncol*. Jul 2010;21(7):1515-1522. doi:10.1093/annonc/mdp573
20. Pfister DG, Cassileth BR, Deng GE, et al. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. *J Clin Oncol*. May 20 2010;28(15):2565-70. doi:10.1200/jco.2009.26.9860
21. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. *J Natl Cancer Inst*. Apr 1 2009;101(7):498-506. doi:10.1093/jnci/djp007
22. Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. *Semin Radiat Oncol*. Jan 2009;19(1):29-34. doi:10.1016/j.semradonc.2008.09.006
23. Salama JK, Haddad RI, Kies MS, et al. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. Nov 1 2009;75(3):725-33. doi:10.1016/j.ijrobp.2008.11.059

**Reviewed / Approved by NIA Clinical Guideline Committee**



## GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.